# Targeting SHP2 with Natural Products: Exploring Saponin-Based Allosteric Inhibitors and Their Therapeutic Potential

## TL;DR

This paper reviews how natural saponins can inhibit SHP2, a protein linked to cancer, by targeting a specific site and improving treatment options.

## Contribution

The paper introduces saponin-based allosteric inhibitors as a novel approach to targeting SHP2 with improved specificity and therapeutic potential.

## Key findings

- Saponins show promise as allosteric inhibitors of SHP2 by interacting with key residues in the tunnel site.
- Natural saponins may overcome limitations of traditional catalytic inhibitors, such as poor selectivity and bioavailability.
- Future strategies include optimizing saponin structures and exploring PROTACs to enhance clinical effectiveness.

## Abstract

SHP2, a non-receptor protein tyrosine phosphatase, plays a pivotal role in regulating intracellular signaling pathways, particularly the RAS/MAPK and PI3K/AKT cascades, which are critical for cellular proliferation, differentiation, and survival. Aberrant SHP2 activity, often driven by gain-of-function mutations, is implicated in oncogenesis and drug resistance, making it an attractive therapeutic target. Traditional inhibitors targeting SHP2’s catalytic site face limitations such as poor selectivity and low bioavailability. Recent advancements in allosteric inhibitors, specifically targeting SHP2’s tunnel site, offer improved specificity and pharmacokinetics. Natural products, especially saponins with their unique structural diversity, have emerged as promising candidates for SHP2 inhibition. This review explores the structural and functional dynamics of SHP2, highlights the potential of saponin-based inhibitors, and discusses their mechanisms of action, including their interactions with key residues in the tunnel site. The therapeutic potential of saponins is further emphasized by their ability to overcome the limitations of catalytic inhibitors and their applicability in combination therapies. Future directions include structural optimization to improve pharmacokinetics and the development of innovative strategies such as PROTACs to enhance the clinical utility of saponin-based SHP2 inhibitors.